“Graft vs. Host Disease- Competitive Landscape, Technology and Pipeline Analysis, 2016”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under the category of Graft Versus Host Disease. Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign.
Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/209352 .
The complexity of immune-mediated disease occurs due to the interaction between the adaptive immunity of donor and recipient. It can progress from mild to severe forms as either acute GVHD (aGVHD) or chronic GVHD (cGVHD). Both aGVHD and cGVHD commonly affect organs such as the skin, gastrointestinal (GI) tract, liver, oral mucosa, and eyes. It is the worldwide cause of mortality and morbidity. Several factors are responsible for Graft versus Host Disease such as blood transfusion, bone marrow transplant, stem cell transplant.
Leading Companies Profiles Analyzed in Report:
- Bellicum Pharmaceuticals
- Kymab Limited
- ImmuneTarget Inc.
- AstraZeneca plc.
- Fate Therapeutics, Inc.
- Therakos Inc.
- Mallinckrodt Pharmaceuticals
- AstraZeneca plc.
Purchase a copy of this report @ http://www.orbisresearch.com/contact/purchase/209352
• The new report, provides a Graft Versus Host Disease Landscape across the globe
- The report provides drug profiles which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, Preclinical and Discovery stages
- Coverage of the Graft Versus Host Disease pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Graft Versus Host Disease and also provide company profiling
- Pipeline products coverage based on various stages of development from NDA filings to discovery.
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type.
Some Points From List Of Tables:
Table 1: Collaboration and Deal Values for Graft Versus Host Disease, 2017
Table 2: Licensing Agreement of Companies for Graft Versus Host Disease, 2017
Table 3: Financing Values of Graft Versus Host Disease
Table 4:Number of Products Under Development for GVHD, 2017
Table 5: Last Stage Products (Phase III and Filed), 2017
Table 6: Mid Stage Products (Phase II), 2017
Table 7: Early Stage Products (Phase I and IND), 2017
Table 8: Pre-Clinical and Discovery Products, 2017
Table 9: Assessment by Monotherapy Products, 2017
Table 10: Assessment by Route Of Administration, 2017
Table 11:Assessment by Stage and Route Of Administration, 2017
Table 12: Assessment by Molecule Type, 2017
Table 13:Assessment by Stage and Molecule Type, 2017
Figure 1:Types of Graft Versus Host Disease, 2017
Figure 2:Symptoms Of Acute Graft Versus Host Disease , 2017
Figure 3:Symptoms Of Chronic Graft Versus Host Disease , 2017
Figure 4: Pathophysiology of Chronic Graft Versus Host Disease, 2017
Figure 5:Leukemia patient received allogeneic HCT from 1995-2015
Figure 6:Non-Leukemia patient received allogeneic HCT from 1995-2015
Figure 7: Collaboration and deal value, 2017
Figure 8: GVHD designation and Number of Products, 2017
Figure 9: GVHD designation by USFDA and EMA, 2017
Figure 10: Number of GVHD Ongoing Clinical Trials & Completion Year, 2017
For any enquires before buying, connect with us @ firstname.lastname@example.org
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +9164101019
For more information contact email@example.com